<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862536</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-008-12F</org_study_id>
    <nct_id>NCT01862536</nct_id>
  </id_info>
  <brief_title>Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease</brief_title>
  <acronym>TADA-PHILD</acronym>
  <official_title>Tadalafil for Pulmonary Hypertension Associated With Chronic Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The functional, social, and economic burden of chronic obstructive lung disease (COPD) on the&#xD;
      healthcare system is extraordinary. COPD is the fourth leading cause of death in the United&#xD;
      States, and some estimates attribute up to $33.2 billion in health care costs to&#xD;
      COPD-associated morbidity and mortality annually. The burden of COPD to the VA Healthcare&#xD;
      system parallels these findings. According to the VA HSR&amp;D Health Economics Resource Center,&#xD;
      COPD ranks 5th among the 40 most common chronic clinical conditions in the U.S. Veteran&#xD;
      patient population, is responsible for &gt;14,000 VA hospital admission annually, and increases&#xD;
      by $1,051/patient the total annual health care cost burden on the VA Healthcare system.&#xD;
      Importantly, COPD is associated with frequent emergency room visitation and/or&#xD;
      hospitalization patients. Pulmonary hypertension is a common co-morbid condition that worsen&#xD;
      morbidity and mortality in patients with COPD. This study will examine the potential for&#xD;
      tadalafil, a phosphodiesterase type-5 (PDE-5) inhibitor to improve functional status by&#xD;
      decreasing pulmonary hypertension. Results from this study are expected to define the&#xD;
      potential use of PDE-5 inhibitors in COPD-induced pulmonary hypertension. If successful, this&#xD;
      treatment option may improve quality of life and outcomes for the large number of Veterans&#xD;
      afflicted with PH due to COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Summary/Abstract This VA CSR&amp;D Merit Review Award for a Clinical Trial proposal&#xD;
      describes a 5-year program to support a prospective, placebo-controlled, randomized clinical&#xD;
      trial (RCT) evaluating the effect of phosphodiesterase type-5 (PDE-5) inhibition with&#xD;
      tadalafil at 40 mg daily over 12 months on exercise capacity in patients with at least&#xD;
      moderate pulmonary hypertension (PH) PH (mean pulmonary artery pressure (mPAP) &gt; 25 mm Hg,&#xD;
      pulmonary vascular resistance (PVR)&gt;3.0 Woods units, pulmonary capillary wedge pressure&#xD;
      (PCWP) &lt;18 mm Hg) due to chronic obstructive pulmonary disease (COPD) GOLD stage II or&#xD;
      higher, FEV1FVC &lt;70). PDE-5 inhibitors are recommended for World Health Organization (WHO)&#xD;
      Category 1 PH but there is no evidence based recommendation supporting the use of these&#xD;
      inhibitors in COPD-induced PH (WHO Category 3). In order to ensure maximum patient enrollment&#xD;
      and to increase the clinical and demographic diversity of patients included in this study,&#xD;
      the proposed research will be conducted at four VA sites: Boston VA Healthcare System,&#xD;
      Providence VA Medical Center, the Greater Los Angeles VA Healthcare System , Atlanta VA and&#xD;
      Denver VA. The research team includes senior investigators with extensive experience in the&#xD;
      clinical management of patients with COPD and PH. The principal investigators (PI) for this&#xD;
      study is Dr. Ronald H. Goldstein (Chief, Pulmonary Medicine at the Boston Healthcare System)&#xD;
      and Dr Sharon Rounds (Chief, Medical Service, Providence VA). Dr Shelley Shapiro will serve&#xD;
      as site PI at the Greater Los Angeles VA Healthcare System.&#xD;
&#xD;
      Within the Veteran population, COPD ranks among the most common chronic diseases and inflicts&#xD;
      a substantial clinical and economic burden on the VA Healthcare System. Importantly, the vast&#xD;
      majority of COPD-associated mortality and morbidity, including hospital admissions, is&#xD;
      derived from a relatively select subpopulation of patients. There is emerging evidence to&#xD;
      suggest that clinically evident PH is a key determinate of risk in COPD for exacerbations and&#xD;
      progression of disease. The investigators found that moderate or severe PH is associated with&#xD;
      significantly increased rates of COPD-related hospital readmission as compared to similar&#xD;
      Veterans with COPD and only mild PH. Moreover, this trend was not influenced by differences&#xD;
      in conventional measures of COPD disease severity (i.e., forced expiratory volume in 1 second&#xD;
      [FEV1]) and was irrespective of supplemental oxygen status. These observations are in support&#xD;
      of previously established clinical observations from others demonstrating that traditional&#xD;
      COPD therapies, including supplemental oxygen, are ineffective at modulating sustained&#xD;
      improvements to cardiopulmonary hemodynamics in patients with COPD and PH. It is established&#xD;
      in specific forms of PH in which hypoxia is not the central mediator of disease progression&#xD;
      that restoration of NO--dependent signaling in pulmonary vascular tissue is effective at&#xD;
      attenuating pulmonary vascular remodeling to improve cardiopulmonary hemodynamics, exercise&#xD;
      tolerance, and quality of life. The extent to which therapies that preserve NO--dependent&#xD;
      signaling in pulmonary vascular tissue are effective in PH due to chronic lung disease,&#xD;
      however, is not known.&#xD;
&#xD;
      Under physiological conditions, the enzyme phosphodiesterase type-5 (PDE-5) functions to&#xD;
      maintain pulmonary vascular tone by degrading cGMP a key signaling intermediary involved in&#xD;
      NO--dependent signaling. However, in PH due to lung disease, pulmonary vascular levels of NO-&#xD;
      are diminished while PDE-5 levels are increased. This raises the possibility that PDE-5&#xD;
      inhibition is a potential strategy by which to increase NO- bioavailability and attenuate PH&#xD;
      in patients with COPD, and sets the framework for the central hypothesis of the current&#xD;
      proposal is that pharmacological inhibition of PDE-5 will improve functional capacity as&#xD;
      assessed by 6 minute walk test in patients with COPD-induced moderate to severe PH. The&#xD;
      secondary outcome measures will assess whether this change in functional status is&#xD;
      accompanied by an improvement in maximal oxygen uptake during cardiopulmonary testing (VO2)&#xD;
      and changes in vascular remodeling as assessed by cardiopulmonary hemodynamics. To test this&#xD;
      hypothesis, a RCT will be conducted using tadalafil (40 mg orally daily) or placebo. The&#xD;
      primary outcome measurements will be the six minute walk test. The secondary outcome measures&#xD;
      will be functional assessment using peak volume of oxygen consumption (VO2) and the&#xD;
      hemodynamic measures of PVR and mPAP. Additional information will be obtained related to the&#xD;
      non-invasive assessment of pulmonary artery systolic pressure and right ventricular (RV)&#xD;
      function including tricuspid annular plane systolic excursion, pulmonary artery acceleration&#xD;
      time, and changes to the pulmonary outflow tract Doppler envelope, dyspnea, health related&#xD;
      quality of life assessed by validated standardized questionnaires and the frequency of COPD&#xD;
      exacerbations after 12 months. Results from this study are expected to define the potential&#xD;
      use of PDE-5 inhibitors in COPD-induced PH. If successful, this treatment option may improve&#xD;
      quality of life and outcomes for the large number of Veterans afflicted with PH due to COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 Minute Walk Test</measure>
    <time_frame>The change in distance walked when assessed at 3 months following trial initiation as compared to baseline, similarly at 6 months compared to baseline, at 9 months compared to baseline and at 12 months compared to baseline.</time_frame>
    <description>Change from baseline in distance walked in 6 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum VO2</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of aerobic fitness on exercise assessed by cardiopulmonary exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Vascular Resistance</measure>
    <time_frame>6 months</time_frame>
    <description>Pulmonary vascular resistance assessed on right heart catheterization is a hemodynamic measurement of pulmonary vascular remodeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pulmonary Artery Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Mean pulmonary artery pressure assessed by right heart catheterization is a hemodynamic measurement of pulmonary hypertension severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid Annular Plane Excursion (TAPSE)</measure>
    <time_frame>12 months</time_frame>
    <description>The tricuspid annular plane excursion is an echocardiographic measurement of right ventricular systolic dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire, Dyspnea and Health Related Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. There are 50 items, 2 parts, (3 components). Each item is accorded a weight determined by the degree of distress accorded to each symptom or state described.&#xD;
Scores range from 0-100, with higher scores indicating more limitations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-type Brain Natriuretic Peptide (BNP) Concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Plasma BNP concentration is a biochemical marker that correlates positively with pulmonary hypertension severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Hypoxemia</measure>
    <time_frame>Early (4 hours and 3 days following treatment) and late (1, 3, 6, 9, 12 months following treatment)</time_frame>
    <description>Changes to resting peripheral oxyhemoglobin saturation levels will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise-induced Hypoxemia</measure>
    <time_frame>12 months</time_frame>
    <description>Changes to peripheral oxyhemoglobin saturation levels on exercise will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily use of tadalafil (study drug) at 40 mg orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Daily use of study drug to treat pulmonary hypertension.</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Daily use in double blind study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female U.S. Veteran patients 40-85 years old, with Gold Stage II COPD by&#xD;
             pulmonary function testing (FEV1/FVC &lt;0.70; performed within 6 months of recruitment.&#xD;
&#xD;
          -  Eligible subjects must have PH documented on transthoracic echocardiogram within 6&#xD;
             months of baseline visit demonstrating an RV systolic pressure &gt;40mmHg. To confirm the&#xD;
             presence of PH, a right-heart catheterization will be performed, with subjects&#xD;
             randomized to treatment only if catheterization shows a:&#xD;
&#xD;
               -  mPAP &gt;25 mm Hg&#xD;
&#xD;
               -  PVR &gt;2.5 Wood units&#xD;
&#xD;
               -  pulmonary artery capillary wedge pressure 18 mm Hg or less at rest&#xD;
&#xD;
          -  PH belonging to the following subgroup of the updated Dana Point Clinical&#xD;
             Classification:&#xD;
&#xD;
               -  Group 3 (PH associated with lung disease and/or hypoxemia) specifically, Group&#xD;
                  3.1 (chronic obstructive pulmonary disease [COPD]) as the major criteria.&#xD;
                  Patients may also have minor clinical features associated with 3.2 (Interstitial&#xD;
                  disease) (such as mild fibrosis on high resolution chest CT, but total lung&#xD;
                  capacity&gt;80% predicted) and 3.3 (sleep disordered breathing) (AHI &lt;15 or&#xD;
                  20/hour).&#xD;
&#xD;
          -  6-minute walk distance between 50-450 meters at screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PH belonging to the following subgroups of the updated Dana Point Clinical&#xD;
             Classification:&#xD;
&#xD;
        Group 1&#xD;
&#xD;
          -  Idiopathic&#xD;
&#xD;
          -  heritable&#xD;
&#xD;
          -  drug or toxin-induced&#xD;
&#xD;
          -  Associated Pulmonary Arterial Hypertension (APAH) with:&#xD;
&#xD;
               -  connective tissue disease&#xD;
&#xD;
               -  congenital heart disease&#xD;
&#xD;
               -  or HIV&#xD;
&#xD;
        Group 2&#xD;
&#xD;
          -  left atrial hypertension&#xD;
&#xD;
        Group 4&#xD;
&#xD;
          -  chronic thromboembolic PH&#xD;
&#xD;
          -  or other forms of PH not associated with primary lung disease&#xD;
&#xD;
        Also&#xD;
&#xD;
          -  Patients with a history of systemic hypotension in the ambulatory setting&#xD;
             (reproducible measurements of systolic blood pressure &lt;89 mmHg) on chart review.&#xD;
&#xD;
          -  Patients with moderate or severe hepatic impairment (Child-Pugh B and C)&#xD;
&#xD;
          -  Patients with severe renal insufficiency (GFR &lt;30 ml/min/1.73 m2)&#xD;
&#xD;
          -  Severe aortic stenosis (aortic valve area &lt;1.0 cm2)&#xD;
&#xD;
          -  Patients with any acute or chronic impairment:&#xD;
&#xD;
               -  (other than dyspnea), limiting the ability to comply with the study requirements,&#xD;
                  including the 6-minute walk test and right heart catheterization.&#xD;
&#xD;
          -  Patients with a recent stroke&#xD;
&#xD;
          -  Patients with untreated hypoxemia (SaO2 &lt;92%) at rest&#xD;
&#xD;
          -  Patients with untreated moderate or severe obstructive sleep apnea (AHI&gt;15)&#xD;
&#xD;
          -  Patients with any coagulopathy&#xD;
&#xD;
          -  Patients requiring nitrate therapy for any clinical indication&#xD;
&#xD;
          -  Patients with an active prescription for pulmonary vasodilator medication other than&#xD;
             oxygen&#xD;
&#xD;
          -  Patients with a history of nonarteritic anterior ischemic optic neuropathy&#xD;
&#xD;
          -  Contraindication to tadalafil use including allergy to:&#xD;
&#xD;
               -  any PDE-5 inhibitor&#xD;
&#xD;
               -  anatomical deformations of the penis&#xD;
&#xD;
               -  sickle cell anemia&#xD;
&#xD;
               -  multiple myeloma&#xD;
&#xD;
               -  leukemia&#xD;
&#xD;
               -  bleeding disorders&#xD;
&#xD;
               -  active peptic ulcer disease&#xD;
&#xD;
               -  retinitis pigmentosa or other retinal disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald H Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence VA Medical Center, Providence, RI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <results_first_submitted>November 20, 2020</results_first_submitted>
  <results_first_submitted_qc>February 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2021</results_first_posted>
  <disposition_first_submitted>July 28, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 3, 2020</disposition_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized trial</keyword>
  <keyword>COPD</keyword>
  <keyword>tadalafil</keyword>
  <keyword>Phosphodiesterase inhibitor</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The PI will create de-identified, study-specific datasets. The PI will replace social security and medical station numbers with study-specific numbers.&#xD;
A local privacy officer will certify that a dataset contains no PHI, PII, or VA Sensitive Information prior to release outside VA.&#xD;
Final data sets will be maintained locally on a secure server or comparable data storage appliance inside the VA network until enterprise-level resources become available for long-term storage and access.</ipd_description>
    <ipd_time_frame>- Datasets meeting VA standards for disclosure to the public will be made available within 1 year of publication.</ipd_time_frame>
    <ipd_access_criteria>Investigators requesting a copy of a dataset will sign a Letter of Agreement or a Data Use Agreement. The recipient will not attempt to identify any individual whose data are in the dataset. A local privacy officer will certify that a dataset contains no PHI, PII, or VA Sensitive Information prior to release outside VA.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01862536/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The discrepancy between the enrollment number (44) and number in the participant flow module (36) was due to participant drop out. Of the 44 consented, 3 declined to participate, 3 did not complete the test dose trial, 1 had a medication conflict and 1 died prior to trial initiation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
        </group>
        <group group_id="P2">
          <title>Tadalafil</title>
          <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
        </group>
        <group group_id="B2">
          <title>Tadalafil</title>
          <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 Minute Walk Test</title>
          <units>Meters walked in 6 minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243.50" lower_limit="182.90" upper_limit="317.00"/>
                    <measurement group_id="B2" value="249.35" lower_limit="189.6" upper_limit="319.4"/>
                    <measurement group_id="B3" value="246.425" lower_limit="186.85" upper_limit="318.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 6 Minute Walk Test</title>
        <description>Change from baseline in distance walked in 6 minutes.</description>
        <time_frame>The change in distance walked when assessed at 3 months following trial initiation as compared to baseline, similarly at 6 months compared to baseline, at 9 months compared to baseline and at 12 months compared to baseline.</time_frame>
        <population>.The Overall Number of Participants Analyzed differs with the number in the Participant Flow because of subject drop out over the study period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6 Minute Walk Test</title>
          <description>Change from baseline in distance walked in 6 minutes.</description>
          <population>.The Overall Number of Participants Analyzed differs with the number in the Participant Flow because of subject drop out over the study period</population>
          <units>Meters walked in 6 minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in 6 MWT from baseline to 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="-2.70" upper_limit="28.00"/>
                    <measurement group_id="O2" value="16.60" lower_limit="-15.20" upper_limit="48.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in 6 MWT from baseline to 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" lower_limit="-12.00" upper_limit="42.00"/>
                    <measurement group_id="O2" value="4.90" lower_limit="-23.40" upper_limit="45.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in 6 MWT from baseline to 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.00" lower_limit="-61.00" upper_limit="32.00"/>
                    <measurement group_id="O2" value="8.93" lower_limit="-24.45" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in 6 MWT from baseline to 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" lower_limit="-9.00" upper_limit="40.00"/>
                    <measurement group_id="O2" value="16.76" lower_limit="-1.70" upper_limit="49.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum VO2</title>
        <description>Measure of aerobic fitness on exercise assessed by cardiopulmonary exercise test.</description>
        <time_frame>12 months</time_frame>
        <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because of subject drop out and patients who required supplemental oxygen did not have a cardiopulmonary exercise test performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum VO2</title>
          <description>Measure of aerobic fitness on exercise assessed by cardiopulmonary exercise test.</description>
          <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because of subject drop out and patients who required supplemental oxygen did not have a cardiopulmonary exercise test performed.</population>
          <units>mL/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13.6" lower_limit="10.3" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Vascular Resistance</title>
        <description>Pulmonary vascular resistance assessed on right heart catheterization is a hemodynamic measurement of pulmonary vascular remodeling.</description>
        <time_frame>6 months</time_frame>
        <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants refused to have a RHC procedure at the 12 month timepoint and therefore the PVR data was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Vascular Resistance</title>
          <description>Pulmonary vascular resistance assessed on right heart catheterization is a hemodynamic measurement of pulmonary vascular remodeling.</description>
          <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants refused to have a RHC procedure at the 12 month timepoint and therefore the PVR data was not available for analysis.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" lower_limit="2.93" upper_limit="5.83"/>
                    <measurement group_id="O2" value="2.69" lower_limit="1.87" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pulmonary Artery Pressure</title>
        <description>Mean pulmonary artery pressure assessed by right heart catheterization is a hemodynamic measurement of pulmonary hypertension severity.</description>
        <time_frame>6 months</time_frame>
        <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants refused to have a RHC procedure at the 12 month timepoint and therefore the mPAP data was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pulmonary Artery Pressure</title>
          <description>Mean pulmonary artery pressure assessed by right heart catheterization is a hemodynamic measurement of pulmonary hypertension severity.</description>
          <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants refused to have a RHC procedure at the 12 month timepoint and therefore the mPAP data was not available for analysis.</population>
          <units>Wood units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.00" lower_limit="28.00" upper_limit="37.50"/>
                    <measurement group_id="O2" value="29.00" lower_limit="25.00" upper_limit="38.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tricuspid Annular Plane Excursion (TAPSE)</title>
        <description>The tricuspid annular plane excursion is an echocardiographic measurement of right ventricular systolic dysfunction.</description>
        <time_frame>12 months</time_frame>
        <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants did not complete an ECHO procedure and therefore TAPSE data was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>Tricuspid Annular Plane Excursion (TAPSE)</title>
          <description>The tricuspid annular plane excursion is an echocardiographic measurement of right ventricular systolic dysfunction.</description>
          <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants did not complete an ECHO procedure and therefore TAPSE data was not available for analysis.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="2.00" upper_limit="2.45"/>
                    <measurement group_id="O2" value="2.12" lower_limit="1.70" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire, Dyspnea and Health Related Quality of Life</title>
        <description>Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. There are 50 items, 2 parts, (3 components). Each item is accorded a weight determined by the degree of distress accorded to each symptom or state described.&#xD;
Scores range from 0-100, with higher scores indicating more limitations</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire, Dyspnea and Health Related Quality of Life</title>
          <description>Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. There are 50 items, 2 parts, (3 components). Each item is accorded a weight determined by the degree of distress accorded to each symptom or state described.&#xD;
Scores range from 0-100, with higher scores indicating more limitations</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.34" lower_limit="43.11" upper_limit="61.04"/>
                    <measurement group_id="O2" value="44.64" lower_limit="36.26" upper_limit="55.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-type Brain Natriuretic Peptide (BNP) Concentration</title>
        <description>Plasma BNP concentration is a biochemical marker that correlates positively with pulmonary hypertension severity.</description>
        <time_frame>12 months</time_frame>
        <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants did not show up for the lab test and therefore the data was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>N-type Brain Natriuretic Peptide (BNP) Concentration</title>
          <description>Plasma BNP concentration is a biochemical marker that correlates positively with pulmonary hypertension severity.</description>
          <population>The Overall Number of Participants Analyzed differs with the number in the Participant Flow because these participants did not show up for the lab test and therefore the data was not available for analysis.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" lower_limit="26.00" upper_limit="365.2"/>
                    <measurement group_id="O2" value="47.81" lower_limit="17.00" upper_limit="98.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Hypoxemia</title>
        <description>Changes to resting peripheral oxyhemoglobin saturation levels will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
        <time_frame>Early (4 hours and 3 days following treatment) and late (1, 3, 6, 9, 12 months following treatment)</time_frame>
        <population>Measurements were not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Hypoxemia</title>
          <description>Changes to resting peripheral oxyhemoglobin saturation levels will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
          <population>Measurements were not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise-induced Hypoxemia</title>
        <description>Changes to peripheral oxyhemoglobin saturation levels on exercise will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
        <time_frame>12 months</time_frame>
        <population>Measurements were not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Tablet</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil</title>
            <description>Daily use of tadalafil (study drug) at 40 mg. orally</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise-induced Hypoxemia</title>
          <description>Changes to peripheral oxyhemoglobin saturation levels on exercise will be used to assess the safety of the study drug in patients with chronic lung diseases.</description>
          <population>Measurements were not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet&#xD;
placebo: Daily use in double blind study.</description>
        </group>
        <group group_id="E2">
          <title>Tadalafil</title>
          <description>Daily use of tadalafil (study drug) at 40 mg orally.&#xD;
Tadalafil: Daily use of study drug to treat pulmonary hypertension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemoptysis</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye floaters</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel obstruction</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>heartburn, dizziness, inability to swallow</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <description>not related to intervention</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial did not reach its enrollment goals. Enrollment was limited because of the unexpected frailty of patients with advanced COPD and evidence of elevated pulmonary artery pressure as assessed by cardiac echo. In addition we found that many potential candidates were found to have features of both group II and group III PH.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ronald Goldstein</name_or_title>
      <organization>VA Boston Healthcare System</organization>
      <phone>857-203-6578</phone>
      <email>Ronald.Goldstein@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

